European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
Bruno B, Wasch R, Engelhardt M, Gay F, Giaccone L, D'Agostino M, Rodriguez-Lobato LG, Danhof S, Gagelmann N, Kroeger N, Popat R, Van De Donk NWCJ, Terpos E, Dimopoulos MA, Sonneveld P, Einsele H, Boccadoro M (2021)
Publication Type: Journal article, Review article
Publication year: 2021
Journal
Book Volume: 106
Pages Range: 2054-2065
Journal Issue: 8
DOI: 10.3324/haematol.2020.276402
Abstract
Chimeric antigen receptor (CAR) T cells (CAR-T) have dramatically changed the treatment landscape of B-cell malignancies, providing a potential cure for relapsed/refractory patients. Long-term responses in patients with acute lymphoblastic leukemia and non Hodgkin lymphomas have encouraged further development in myeloma. In particular, B-cell maturation antigen (BCMA)-targeted CAR-T have established very promising results in heavily pre-treated patients. Moreover, CAR-T targeting other antigens (i.e., SLAMF7 and CD44v6) are currently under investigation. However, none of these current autologous therapies have been approved, and despite high overall response rates across studies, main issues such as long-term outcome, toxicities, treatment resistance, and management of complications limit as yet their widespread use. Here, we critically review the most important pre-clinical and clinical findings, recent advances in CAR-T against myeloma, as well as discoveries in the biology of a still incurable disease, that, all together, will further improve safety and efficacy in relapsed/refractory patients, urgently in need of novel treatment options.
Involved external institutions
Hospital Clínic de Barcelona
Spain (ES)
University of Turin / Università degli Studi di Torino (UNITO)
Italy (IT)
Albert-Ludwigs-Universität Freiburg
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
King's College Hospital (KCH)
United Kingdom (GB)
University of Amsterdam
Netherlands (NL)
National and Kapodistrian University of Athens
Greece (GR)
Erasmus University Medical Center (MC)
Netherlands (NL)
Spain (ES)
University of Turin / Università degli Studi di Torino (UNITO)
Italy (IT)
Albert-Ludwigs-Universität Freiburg
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
King's College Hospital (KCH)
United Kingdom (GB)
University of Amsterdam
Netherlands (NL)
National and Kapodistrian University of Athens
Greece (GR)
Erasmus University Medical Center (MC)
Netherlands (NL)
How to cite
APA:
Bruno, B., Wasch, R., Engelhardt, M., Gay, F., Giaccone, L., D'Agostino, M.,... Boccadoro, M. (2021). European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma. Haematologica, 106(8), 2054-2065. https://doi.org/10.3324/haematol.2020.276402
MLA:
Bruno, Benedetto, et al. "European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma." Haematologica 106.8 (2021): 2054-2065.
BibTeX: Download